Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial
Dow Jones
Aug 12
Definium Therapeutics said a late-stage trial of its treatment for generalized anxiety disorder met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement compared with placebo.
The biopharmaceutical company on Wednesday said the results mark the second positive late-stage trial readout for the treatment, DT120, which was previously found to help manage major depressive disorder.
DT120 was generally well tolerated in the recent Voyage study, and no new safety signals were identified.
"The unprecedented efficacy demonstrated in Voyage should raise the bar for what patients and clinicians expect from GAD treatments and reinforces our belief that DT120 has the potential to redefine care for the millions of patients in need," Chief Executive Rob Barrow said.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.